source
- FDA approves Roivant's oral dermatomyositis drug Lisraya (brepocitinib)The U.S. Food and Drug Administration has granted approval to Roivant's drug brepocitinib, which will be sold under the brand name Lisraya. The decision marks the first major regulatory clearance f…
- Revolution Medicines' Rasonge receives second-line pancreatic cancer nod, could drive $2.3B sales by 2028Revolution Medicines announced that its RAS inhibitor Rasonge earned a second-line indication for pancreatic ductal adenocarcinoma, marking the first regulatory step in the company's PDAC strategy.…